bristol myers biontech - Search News

News

BioNTech, Bristol-Myers Squibb and cancer immunotherapy

Seeking Alpha · 8h

Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I like BMY more than BNTX.

Reuters on MSN · 4d

Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy

By Ludwig Burger and Michael Erman (Reuters) -Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's next-generation cancer immunotherapy,

MarketWatch on MSN · 4d

Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer’s deal announced two weeks earlier.

Medical Dialogues13h

Bristol Myers Squibb, BioNTech ink pact to co-develop, co-commercialize investigational bispecific antibody for multiple solid tumor types

Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...

GEN - Genetic Engineering and Biotechnology News2d

BMS, BioNTech Ink Up-to-$11B Cancer Bispecific Antibody Collaboration

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results